Suchen Sie in klinischen Studien nach: Gossypol

Insgesamt 25 ergebnisse

    • NCT00848016
      Abgeschlossen
      Bedingungen: Recurrent Adrenocortical Carcinoma; Stage III Adrenocortical Carcinoma; Stage IV Adrenocortical Carcinoma
    • NCT01977209
      Unbekannter Status
      Bedingungen: Non-small Cell Lung Cancer
    • NCT00540722
      Abgeschlossen
      Bedingungen: Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Recurrent Adult Brain Tumor
    • NCT00773955
      Abgeschlossen
      Bedingungen: Extensive Stage Small Cell Lung Cancer; Recurrent Small Cell Lung Cancer
    • NCT00666666
      Abgeschlossen
      Bedingungen: Adenocarcinoma of the Prostate; Stage IV Prostate Cancer
    • NCT00544596
      Abgeschlossen
      Bedingungen: Extensive Stage Small Cell Lung Cancer; Unspecified Adult Solid Tumor, Protocol Specific
    • NCT01003769
      Beendet
      Bedingungen: Recurrent Chronic Lymphocytic Leukemia
    • NCT00286793
      Abgeschlossen
      Bedingungen: Prostate Cancer
    • NCT00286780
      Abgeschlossen
      Bedingungen: Chronic Lymphocytic Leukemia
    • NCT00988169
      Beendet
      Bedingungen: Lung Cancer
    • NCT00934076
      Zurückgezogen
      Bedingungen: Carcinoma, Non Small Cell Lung
    • NCT02697344
      Aktiv, nicht rekrutierend
      Bedingungen: Recurrent Plasma Cell Myeloma
    • NCT00561197
      Beendet
      Bedingungen: Locally Advanced Esophageal or GE Junction Cancer
    • NCT00275431
      Abgeschlossen
      Bedingungen: Follicular Lymphoma; Diffuse Large Cell Lymphoma; Mantle Cell Lymphoma; Small Lymphocytic Lymphoma; Chronic Lymphocytic Leukemia
    • NCT00891072
      Abgeschlossen
      Bedingungen: Adult Grade III Lymphomatoid Granulomatosis; Adult Nasal Type Extranodal NK/T-cell Lymphoma; Contiguous Stage II Adult Burkitt Lymphoma; Contiguous Stage II Adult Diffuse Large Cell Lymphoma; Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Contiguous Stage II Adult Lymphoblastic Lymphoma; Contiguous Stage II Grade 1 Follicular Lymphoma; Contiguous Stage II Grade 2 Follicular Lymphoma; Contiguous Stage II Grade 3 Follicular Lymphoma; Contiguous Stage II Mantle Cell Lymphoma; Contiguous Stage II Marginal Zone Lymphoma; Contiguous Stage II Small Lymphocytic Lymphoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Nodal Marginal Zone B-cell Lymphoma; Noncontiguous Stage II Adult Burkitt Lymphoma; Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Noncontiguous Stage II Adult Lymphoblastic Lymphoma; Noncontiguous Stage II Grade 1 Follicular Lymphoma; Noncontiguous Stage II Grade 2 Follicular Lymphoma; Noncontiguous Stage II Grade 3 Follicular Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Noncontiguous Stage II Marginal Zone Lymphoma; Noncontiguous Stage II Small Lymphocytic Lymphoma; Peripheral T-cell Lymphoma; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Grade III Lymphomatoid Granulomatosis; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Small Lymphocytic Lymphoma; Splenic Marginal Zone Lymphoma; Stage I Adult Burkitt Lymphoma; Stage I Adult Diffuse Large Cell Lymphoma; Stage I Adult Diffuse Mixed Cell Lymphoma; Stage I Adult Diffuse Small Cleaved Cell Lymphoma; Stage I Adult Immunoblastic Large Cell Lymphoma; Stage I Adult Lymphoblastic Lymphoma; Stage I Grade 1 Follicular Lymphoma; Stage I Grade 2 Follicular Lymphoma; Stage I Grade 3 Follicular Lymphoma; Stage I Mantle Cell Lymphoma; Stage I Marginal Zone Lymphoma; Stage I Small Lymphocytic Lymphoma; Stage III Adult Burkitt Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Mixed Cell Lymphoma; Stage III Adult Diffuse Small Cleaved Cell Lymphoma; Stage III Adult Immunoblastic Large Cell Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Mantle Cell Lymphoma; Stage III Marginal Zone Lymphoma; Stage III Small Lymphocytic Lymphoma; Stage IV Adult Burkitt Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Mixed Cell Lymphoma; Stage IV Adult Diffuse Small Cleaved Cell Lymphoma; Stage IV Adult Immunoblastic Large Cell Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma; Stage IV Marginal Zone Lymphoma; Stage IV Small Lymphocytic Lymphoma; Unspecified Adult Solid Tumor, Protocol Specific; Waldenström Macroglobulinemia
    • NCT00286806
      Abgeschlossen
      Bedingungen: Hormone Refractory Prostate Cancer
    • NCT01285635
      Beendet
      Bedingungen: Squamous Cell Carcinoma of the Head and Neck (SCCHN)
    • NCT00544960
      Abgeschlossen
      Bedingungen: Non-small Cell Lung Cancer
    • NCT00397293
      Abgeschlossen
      Bedingungen: Small Cell Lung Cancer
    • NCT00571675
      Abgeschlossen
      Bedingungen: Hormone Refractory Prostate Cancer
    • NCT01633541
      Aktiv, nicht rekrutierend
      Bedingungen: Laryngeal Cancer
    • NCT00440388
      Abgeschlossen
      Bedingungen: Follicular Lymphoma
    • NCT00390403
      Abgeschlossen
      Bedingungen: Brain and Central Nervous System Tumors
    • NCT04764448
      Rekrutierung
      Bedingungen: Alpha 1-Antitrypsin Deficiency
    • NCT00244374
      Abgeschlossen
      Bedingungen: Medication Adherence; Substance Abuse, Intravenous; Risk Behavior; Hepatitis A; Hepatitis B; Hepatitis C